PHOENIX ― Gastrointestinal cancers are some of the most commonly diagnosed cancers, and they continue to be associated with poor survival outcomes. The drug adagrasib specifically targets the KRASG12C gene mutation that is common in gastrointestinal cancers and inhibits gastrointestinal function.
Trending
- Why Advanced IBD Therapies Fail (GI & Endoscopy News)
- AI in prior authorization: the new gatekeeper (KevinMD)
- Physicians finally got a Medicare raise. Keeping it is the hard part. (Medical Economics)
- Arkansas lab pays $30M to settle kickback allegations tied to gastroenterology practices (Becker’s GI & Endoscopy)
- Fluorescent nanosensor enables rapid, first-of-its-kind detection of key gut health biomarker (MIT News)
- Text Messaging and FIT Completion in a Quality Improvement Trial (ReachMD)
- Combined GI Procedures Are Becoming Routine – AI Can Help Address the Gap in Upper GI Quality Standards (MedCity News)
- Endoscopic Robotics Company Channel Robotics Raises $4.6 Million (PR Newswire)
